Payment overview · 2025
General Payments
$340.90
19 reported records · 11 companies
Healthcare provider profile · identity verified
Vyacheslav Isakov, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WICKLIFFE, OH · NPI 1407826803
Verified facts
What the public records show
CMS Open Payments records show Vyacheslav Isakov, M.D. received $340.90 in general payments during 2025 across 19 reported records.
Lilly USA, LLC accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.78 | 16.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.99 | 13.5% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $40.54 | 11.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.03 | 10.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.91 | 10.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.76 | 10.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.24 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.81 | 5.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.51 | 5.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.74 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.59 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $340.90 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.78 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.99 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.99 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $40.54 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.03 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.76 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 138 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 302 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 293 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 63 |
| Gabapentin | Gabapentin | 192 | 42 |
| Losartan Potassium | Losartan Potassium | 185 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 41 |
| Potassium Chloride | Potassium Chloride | 162 | 39 |
| Furosemide | Furosemide | 161 | 37 |
| Lisinopril | Lisinopril | 154 | 42 |
| Eliquis | Apixaban | 138 | 28 |
| Omeprazole | Omeprazole | 122 | 33 |
| Metformin Hcl | Metformin Hcl | 120 | 27 |
| Sertraline Hcl | Sertraline Hcl | 116 | 18 |
| Allopurinol | Allopurinol | 114 | 26 |
| Trazodone Hcl | Trazodone Hcl | 114 | 38 |
| Carvedilol | Carvedilol | 111 | 30 |
| Jardiance | Empagliflozin | 110 | 16 |
| Mirtazapine | Mirtazapine | 100 | 18 |
| Finasteride | Finasteride | 93 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 14 |
| Tramadol Hcl | Tramadol Hcl | 87 | 30 |
| Simvastatin | Simvastatin | 85 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 30 |
| Fenofibrate | Fenofibrate | 80 | 15 |
| Trulicity | Dulaglutide | 80 | 16 |
| Montelukast Sodium | Montelukast Sodium | 79 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 20 |
| Repaglinide | Repaglinide | 76 | suppressed |
| Famotidine | Famotidine | 71 | 16 |
| Ammonium Lactate | Ammonium Lactate | 67 | 17 |
| Alprazolam | Alprazolam | 66 | 12 |
| Ezetimibe | Ezetimibe | 66 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 13 |
| Myrbetriq | Mirabegron | 62 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 26 |
| Meclizine Hcl | Meclizine Hcl | 61 | 17 |
| Buspirone Hcl | Buspirone Hcl | 59 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 13 |
| Prednisone | Prednisone | 56 | 38 |
| Azithromycin | Azithromycin | 55 | 43 |
| Ozempic | Semaglutide | 55 | 12 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Memantine Hcl Er | Memantine Hcl | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 18 |
| Ketoconazole | Ketoconazole | 48 | suppressed |
| Linzess | Linaclotide | 48 | 15 |
| Topiramate | Topiramate | 48 | suppressed |
| Lovastatin | Lovastatin | 45 | 12 |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Glipizide | Glipizide | 44 | 15 |
| Nifedipine Er | Nifedipine | 44 | 11 |
| Atenolol | Atenolol | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | suppressed |
| Torsemide | Torsemide | 43 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 14 |
| Hydrocortisone | Hydrocortisone | 41 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 16 |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Cefdinir | Cefdinir | 32 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Loperamide | Loperamide Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 11 |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $340.90 · 19 records | Lilly USA, LLC | Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, VOQUEZNA, WATCHMAN Access System, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error